Browsing Tag
AbbVie
67 posts
Can short-acting psychedelics solve the scalability problem in depression treatment?
Short-acting psychedelics like bretisilocin could reshape mental health treatment. Can they overcome the clinical bottlenecks faced by psilocybin and ketamine?
AbbVie’s $1.2bn bet on Gilgamesh’s bretisilocin signals a bold push into next-generation antidepressants
AbbVie to acquire Gilgamesh’s bretisilocin for up to $1.2B to expand its psychiatry pipeline. Find out how this short-acting psychedelic could reshape MDD care.
Glenmark’s AbbVie deal: Can ISB 2001 make it India’s first true global biologics play?
Glenmark’s AbbVie deal for trispecific antibody ISB 2001 could redefine India’s role in global biologics—find out why this partnership matters now.
Why off-the-shelf CAR T therapies are attracting billion-dollar deals despite early-stage risks
Big pharma is betting billions on off-the-shelf CAR T therapies. Can allogeneic platforms overcome early-stage risks to transform cancer care?
Glenmark Pharmaceuticals surges 10% after AbbVie licensing deal boosts ISB 2001 global reach
Glenmark Pharmaceuticals stock jumps 10% after announcing ISB 2001 licensing deal with AbbVie; find out what this could mean for its oncology ambitions.
Why amylin is gaining pharma attention in obesity drug development: From amycretin to AZD6234
Discover how Novo Nordisk, AstraZeneca, and others are betting on amylin-based obesity drugs like amycretin and AZD6234 to reshape metabolic care.
AbbVie to acquire Capstan Therapeutics for $2.1bn to expand in vivo CAR-T platform for autoimmune therapy
AbbVie will acquire Capstan Therapeutics for $2.1B, gaining in vivo CAR-T platform and lead asset CPTX2309 in autoimmune therapy. Read full acquisition details.
REGENXBIO monetizes gene therapy royalties in $250m deal with HCRx
REGENXBIO advances strategic funding deal with Healthcare Royalty to monetize Zolgensma and pipeline royalties while preserving upside from NAV platform assets and AbbVie/Nippon Shinyaku partnerships.
AbbVie’s ELAHERE demonstrates 32% reduction in death risk for ovarian cancer patients
A final analysis of the Phase 3 MIRASOL trial has confirmed that ELAHERE (mirvetuximab soravtansine-gynx) provides a significant…
AbbVie to develop amylin analog for obesity treatment in $350m licensing deal with Gubra
AbbVie has taken a significant step into obesity treatment through a licensing agreement with Denmark-based Gubra, a company…